-
Je něco špatně v tomto záznamu ?
Next-generation sequencing in the molecular classification of endometrial carcinomas: Experience with 270 cases suggesting a potentially more aggressive clinical behavior of multiple classifier endometrial carcinomas
K. Michalova, A. Strakova-Peterikova, O. Ondic, T. Vanecek, M. Michal, N. Hejhalova, P. Holub, P. Slavik, A. Hluchy, P. Gettse, O. Daum, M. Svajdler, M. Michal, J. Presl
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
Grantová podpora
SVV 260652
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
ProQuest Central
od 2003-01-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 2003-01-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 2003-01-01 do Před 1 rokem
- MeSH
- dospělí MeSH
- imunohistochemie MeSH
- lidé středního věku MeSH
- lidé MeSH
- mutace MeSH
- mutační analýza DNA MeSH
- nádorové biomarkery * genetika analýza MeSH
- nádorový supresorový protein p53 genetika MeSH
- nádory endometria * genetika patologie klasifikace MeSH
- prospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vysoce účinné nukleotidové sekvenování * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
Molecular classification of endometrial carcinomas (EC) divides these neoplasms into four distinct subgroups based on their molecular background. Given its clinical significance, genetic examination is becoming integral to the diagnostic process. This study aims to share our experience with the molecular classification of EC using immunohistochemistry (IHC) and next-generation sequencing (NGS). We included all ECs diagnosed at two institutions from 2020 to the present. All cases were prospectively examined by IHC for MMR proteins and p53, followed by NGS using a customized panel covering 18 genes, based on which ECs were classified into four molecular subgroups: POLE mutated, hypermutated (MMR deficient), no specific molecular profile (NSMP), and TP53 mutated. The cohort comprised 270 molecularly classified ECs: 18 (6.6%) POLE mutated, 85 (31.5%) hypermutated, 137 (50.7%) NSMP, and 30 (11.1%) TP53 mutated. Twelve cases (4.4%) were classified as 'multiple classifier' EC. Notably, most of these cases with available follow-up (6/9) behaved aggressively. Within the POLEmut EC group, 3/4 cases had advanced tumors, including one patient who died of the disease. Similarly, in the MMRd/TP53mut group, 3/5 patients with available follow-up had metastatic disease, leading to death of the patient in 1 case. ECs of NSMP showed multiple genetic alterations, with the most common mutations being PTEN (44% within the group of NSMP), followed by PIK3CA (30%), ARID1A (21%), and KRAS (9%). Our findings suggest that combining immunohistochemistry with NGS offers a more reliable classification of ECs, including 'multiple classifier' cases, which, based on our observations, tend to exhibit aggressive behavior. Additionally, our data highlight the complex genetic background of NSMP ECs, which can facilitate further stratification of tumors within this group and potentially help select patients for dedicated clinical trials.
Biopticka Laboratory Ltd Plzen Czech Republic
Faculty of Medicine in Plzen Charles University Plzen Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25022580
- 003
- CZ-PrNML
- 005
- 20251023080439.0
- 007
- ta
- 008
- 251014s2025 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00428-024-03996-1 $2 doi
- 035 __
- $a (PubMed)39676078
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Michalova, Kvetoslava $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic. kveta.michalova@biopticka.cz $u Biopticka Laboratory, Ltd, Plzen, Czech Republic. kveta.michalova@biopticka.cz $1 https://orcid.org/0000000332316870 $7 xx0236038
- 245 10
- $a Next-generation sequencing in the molecular classification of endometrial carcinomas: Experience with 270 cases suggesting a potentially more aggressive clinical behavior of multiple classifier endometrial carcinomas / $c K. Michalova, A. Strakova-Peterikova, O. Ondic, T. Vanecek, M. Michal, N. Hejhalova, P. Holub, P. Slavik, A. Hluchy, P. Gettse, O. Daum, M. Svajdler, M. Michal, J. Presl
- 520 9_
- $a Molecular classification of endometrial carcinomas (EC) divides these neoplasms into four distinct subgroups based on their molecular background. Given its clinical significance, genetic examination is becoming integral to the diagnostic process. This study aims to share our experience with the molecular classification of EC using immunohistochemistry (IHC) and next-generation sequencing (NGS). We included all ECs diagnosed at two institutions from 2020 to the present. All cases were prospectively examined by IHC for MMR proteins and p53, followed by NGS using a customized panel covering 18 genes, based on which ECs were classified into four molecular subgroups: POLE mutated, hypermutated (MMR deficient), no specific molecular profile (NSMP), and TP53 mutated. The cohort comprised 270 molecularly classified ECs: 18 (6.6%) POLE mutated, 85 (31.5%) hypermutated, 137 (50.7%) NSMP, and 30 (11.1%) TP53 mutated. Twelve cases (4.4%) were classified as 'multiple classifier' EC. Notably, most of these cases with available follow-up (6/9) behaved aggressively. Within the POLEmut EC group, 3/4 cases had advanced tumors, including one patient who died of the disease. Similarly, in the MMRd/TP53mut group, 3/5 patients with available follow-up had metastatic disease, leading to death of the patient in 1 case. ECs of NSMP showed multiple genetic alterations, with the most common mutations being PTEN (44% within the group of NSMP), followed by PIK3CA (30%), ARID1A (21%), and KRAS (9%). Our findings suggest that combining immunohistochemistry with NGS offers a more reliable classification of ECs, including 'multiple classifier' cases, which, based on our observations, tend to exhibit aggressive behavior. Additionally, our data highlight the complex genetic background of NSMP ECs, which can facilitate further stratification of tumors within this group and potentially help select patients for dedicated clinical trials.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a nádory endometria $x genetika $x patologie $x klasifikace $7 D016889
- 650 12
- $a vysoce účinné nukleotidové sekvenování $7 D059014
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a mutace $7 D009154
- 650 12
- $a nádorové biomarkery $x genetika $x analýza $7 D014408
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a nádorový supresorový protein p53 $x genetika $7 D016159
- 650 _2
- $a mutační analýza DNA $7 D004252
- 650 _2
- $a prospektivní studie $7 D011446
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Strakova-Peterikova, Andrea $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Ondic, Ondrej $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Vanecek, Tomas $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Michal, Michael $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Hejhalova, Nikola $u Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic
- 700 1_
- $a Holub, Petr $u Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic
- 700 1_
- $a Slavik, Petr $u Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic
- 700 1_
- $a Hluchy, Adam $u Faculty of Medicine in Plzen, Charles University, Plzen, Czech Republic
- 700 1_
- $a Gettse, Polina $u Department of Gynaecology and Obstetrics, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic
- 700 1_
- $a Daum, Ondrej $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Svajdler, Marian $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Michal, Michal $u Department of Pathology, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic $u Biopticka Laboratory, Ltd, Plzen, Czech Republic
- 700 1_
- $a Presl, Jiri $u Department of Gynaecology and Obstetrics, Faculty of Medicine in Plzen, University Hospital Plzen, Charles University, Plzen, Czech Republic
- 773 0_
- $w MED00004660 $t Virchows Archiv $x 1432-2307 $g Roč. 487, č. 1 (2025), s. 141-152
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39676078 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20251014 $b ABA008
- 991 __
- $a 20251023080444 $b ABA008
- 999 __
- $a ok $b bmc $g 2417385 $s 1260743
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 487 $c 1 $d 141-152 $e 20241215 $i 1432-2307 $m Virchows Archiv $n Virchows Arch $x MED00004660
- GRA __
- $a SVV 260652 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20251014
